Phototherapy of mycosis fungoides

Photodermatology Photoimmunology and Photomedicine

Volumn 27, Issue 2, 2011, Pages 68-74

  Trautinger, Franz ^a,b  

^a Karl Landsteiner Institute for Dermatological Research   (Austria)

^b Karl Landsteiner Institute for Implementation of Innovative Techniques in Cardiac Surgery   (Austria)

Author keywords

Cutaneous T cell lymphomas; Mycosis fungoides; Narrowband UVB; PUVA

Indexed keywords

ALPHA INTERFERON; BEXAROTENE; CARMUSTINE; CORTICOSTEROID; ETRETIN; ETRETINATE; ISOTRETINOIN; METHOXSALEN;

BLISTER; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL FEATURE; EDEMA; ERYTHEMA; HUMAN; LASER; MYCOSIS FUNGOIDES; NAUSEA; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; PUVA; RETROSPECTIVE STUDY; REVIEW; SYSTEMIC THERAPY; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; X IRRADIATION;

HUMANS; METHOXSALEN; MYCOSIS FUNGOIDES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 79952525778     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2011.00559.x     Document Type: Review

References (74)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology 2009; 523-531.
3. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009; 113: 5064-5073.
4. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007; 143: 854-859.
5. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary syndrome: validation of the revised international society for cutaneous lymphomas/European organisation for research and treatment of cancer staging proposal. J Clin Oncol 2010; 28: 4730-4739.
6. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med 2004; 350: 1978-1988.
7. Bunn PA Jr, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 1994; 121: 592-602.
8. Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006; 42: 1014-1030.
9. Bunn PA Jr, Lamberg SI. Report of the committee on staging and classification of cutaneous T-cell lymphomas. Cancer Treat Rep 1979; 63: 725-728.
10. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-1722.
11. Willemze R, Dreyling M. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20: iv115-iv118.
12. Whittaker SJ, Marsden JR, Spittle M, Russell-Jones R. Joint British association of dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Brit J Dermatol 2003; 149: 1095-1107.
13. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005; 115: 798-812.
14. Kaye FJ, Bunn PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-1790.
15. Kricker A, Armstrong BK, Hughes AM, et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer 2008; 122: 144-154.
16. Veierod MB, Smedby KE, Lund E, Adami HO, Weiderpass E. Pigmentary characteristics, UV radiation exposure, and risk of non-Hodgkin lymphoma: a prospective study among Scandinavian women. Cancer Epidemiol Biomarkers Prev 2010; 19: 1569-1576.
17. McGregor JM, Crook T, Fraser-Andrews EA, et al. Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol 1999; 112: 317-321.
18. Gilchrest BA, Parrish JA, Tanenbaum L, Haynes HA, Fitzpatrick TB. Oral methoxsalen photochemotherapy of mycosis fungoides. Cancer 1976; 38: 683-689.
19. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987; 316: 297-303.
20. Knobler R, Barr ML, Couriel DR, et al. Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol 2009; 61: 652-665.
21. Zic JA. The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003; 16: 337-346.
22. Farkas A, Kemeny L, French LE, Dummer R. New and experimental skin-directed therapies for cutaneous lymphomas. Skin Pharmacol Physiol 2009; 22: 322-334.
23. Oberholzer PA, Cozzio A, Dummer R, French LE, Hofbauer GFL. Granulomatous slack skin responds to UVA1 phototherapy. Dermatol 2009; 219: 268-271.
24. Hegyi J, Frey T, Arenberger P. The treatment of unilesional mycosis fungoides with methyl aminolevulinate-photodynamic therapy. J Eur Acad Dermatol Venereol 2008; 22: 1134-1135.
25. Edstrom DW, Hedblad M-A. Long-term follow-up of photodynamic therapy for mycosis fungoides. Acta Derm Venereol 2008; 88: 288-290.
26. Recio ED, Zambrano B, Alonso ML, et al. Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature. Int J Dermatol 2008; 47: 410-413.
27. Roupe G. Hypopigmented mycosis fungoides in a child successfully treated with UVA1-light. Pediatr Dermatol 2005; 22: 82.
28. Breuckmann F, von Kobyletzki G, Avermaete A, Kreuter A, Altmeyer P. Efficacy of ultraviolet A1 phototherapy on the expression of bcl-2 in atopic dermatitis and cutaneous T-cell lymphoma in vivo: a comparison study. Photodermatol Photoimmunol Photomed 2002; 18: 217-222.
29. Passeron T, Zakaria W, Ostovari N, et al. Efficacy of the 308-nm excimer laser in the treatment of mycosis fungoides. Arch Dermatol 2004; 140: 1291-1293.
30. Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol 2009; 60: 39-50.
31. Herrmann JJ, Roenigk HH Jr, Hönigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995; 9: 1077-1088.
32. Hönigsmann H, Tanew A. Photo(chemo)therapy for cutaneous T-cell lymphoma. In: Krutmann J, Hönigsmann H, Elmets CA, eds. Dermatologic phototherapy and photodiagnostic methods, 2nd edn. Heidelberg, Berlin: Springer, 2009; 135-149.
33. Hönigsmann H, Brenner W, Rauschmeier W, Konrad K, Wolff K. Photochemotherapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1984; 10: 238-245.
34. Querfeld C, Rosen ST, Kuzel TM, et al. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 2005; 141: 305-311.
35. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the EORTC-cutaneous lymphoma project group. J Am Acad Dermatol 2002; 47: 364-370.
36. Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Rad Oncol Biol Phys 1999; 43: 951-958.
37. Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides. Arch Dermatol 2003; 139: 165-173.
38. Holzle E, Honigsmann H, Rocken M, Ghoreschi K, Lehmann P. Recommendations for phototherapy and photochemotherapy. J Dtsch Dermatol Ges 2003; 1: 985-997.
39. British Photodermatology Group. British Photodermatology Group guidelines for PUVA. Brit J Dermatol 1994; 130: 246-255.
40. Weber F, Schmuth M, Sepp N, Fritsch P. Bath-water PUVA therapy with 8-methoxypsoralen in mycosis fungoides. Acta Derm Venereol 2005; 85: 329-332.
41. Morison WL, Baughman RD, Day RM, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol 1998; 134: 595-598.
42. Stern RS. Malignant melanoma in patients treated for psoriasis with PUVA. Photodermatol Photoimmunol Photomed 1999; 15: 37-38.
43. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-1585.
44. Tura S, Mazza P, Zinzani PL, et al. Alpha recombinant interferon in the treatment of mycosis fungoides (MF). Haematologica 1987; 72: 337-340.
45. Olsen EA, Rosen ST, Vollmer RT, et al. Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 1989; 20: 395-407.
46. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther 2006; 19: 264-271.
47. Stadler R, Kremer A. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Sem Oncol 2006; 33: S7-S10.
48. Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma 2000; 1 (Suppl 1): S41-S44.
49. Stadler R. Optimal combination with PUVA: rationale and clinical trial update. Oncology 2007; 21: 29-32.
50. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.
51. Papadavid E, Antoniou C, Nikolaou V, et al. Safety and efficacy of low-dose bexarotene and PUVA in the treatment of patients with mycosis fungoides. Am J Clin Dermatol 2008; 9: 169-173.
52. Stern DK, Lebwohl M. Treatment of mycosis fungoides with oral bexarotene combined with PUVA. J Drugs Dermatol 2002; 1: 134-136.
53. Singh F, Lebwohl MG. Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series. J Am Acad Dermatol 2004; 51: 570-573.
54. Rodriguez-Vazquez M, Garcia-Arpa M, Gonzalez-Garcia J. Juvenile mycosis fungoides treated with bexarotene and PUVA. Int J Dermatol 2007; 46: 99-102.
55. Michaelis S, Cozzio A, Kempf W, Graf P, Burg G, Dummer R. Combination of bexarotene and psoralen-UVA therapy in a patient with Mycosis fungoides. Dermatol 2004; 209: 72-74.
56. McGinnis KS, Shapiro M, Vittorio CC, Rook AH, Junkins-Hopkins JM. Psoralen plus long-wave UV-A (PUVA) and bexarotene therapy: an effective and synergistic combined adjunct to therapy for patients with advanced cutaneous T-cell lymphoma. Arch Dermatol 2003; 139: 771-775.
57. Coors EA, Von den Driesch P. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A. Brit J Dermatol 2005; 152: 1379-1381.
58. Coors E. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides. Dermatol Clin 2008; 26 (Suppl 1): 33-35.
59. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-3581.
60. Abel EA, Sendagorta E, Hoppe RT. Cutaneous malignancies and metastatic squamous cell carcinoma following topical therapies for mycosis fungoides. J Am Acad Dermatol 1986; 14: 1029-1038.
61. Boer J, Schothorst AA, Suurmond D. Ultraviolet B phototherapy for psoriasis in sunlight-responsive patients. Lancet 1979; 313: 773.
62. Milstein HI, Vonderheid E, Van Scott EJ, Johnson WC. Home ultraviolet phototherapy of early mycosis fungoides: preliminary observations. J Am Acad Dermatol 1982; 6: 355-362.
63. Resnik KS, Vonderheid EC. Home UV phototherapy of early mycosis fungoides: long-term follow-up observations in thirty-one patients. J Am Acad Dermatol 1993; 29: 73-77.
64. van Weelden H, De La Faille HB, Young E, van der Leun JC. A new development in UVB phototherapy of psoriasis. Brit J Dermatol 1988; 119: 11-19.
65. Parrish JA, Jaenicke KF. Action spectrum for the phototherapy of psoriasis. J Invest Dermatol 1981; 1981: 359-362.
66. Gordon P, Diffey B, Matthews J, Farr P. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol 1999; 41: 728-732.
67. Hofer A, Cerroni L, Kerl H, Wolf P. Narrowband (311 nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol 1999; 135: 1377-1380.
68. Diederen PVMM, van Weelden H, Sanders CJG, Toonstra J, Van Vloten WA. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003; 48: 215-219.
69. Ahmad K, Rogers S, McNicholas PD, Collins P. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study. Acta Derm Venereol 2007; 87: 413-417.
70. Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Brit J Dermatol 2004; 151: 283-297.
71. Dummer R, Assaf C, Bagot M, et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer 2007; 43: 2321-2329.
72. Dummer R, Asagoe K, Cozzio A, et al. Recent advances in cutaneous lymphomas. J Dermatol Sci 2007; 48: 157-167.
73. Scheffer E, Meijer CJ, Van Vloten WA. Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides. Cancer 1980; 45: 137-148.
74. Sausville EA, Worsham GF, Matthews MJ, et al. Histologic assessment of lymph nodes in mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma): clinical correlations and prognostic import of a new classification system. Hum Pathol 1985; 16: 1098-1109.